ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Recruitment status was Active, not recruiting
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 22, 2009 | ||||
Last Updated Date | March 18, 2010 | ||||
Start Date ICMJE | May 2009 | ||||
Estimated Primary Completion Date | October 2009 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
The primary endpoint will be the percentage of each wound that has epithelialized during the 21-day treatment period comparing the ACCS-treated wound with the saline-treated wound. [ Time Frame: 21 days ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00886470 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns | ||||
Official Title ICMJE | Phase I/II Randomized Blinded Safety and Dose-determining Efficacy Trial Comparing Accs (Amnion-derived Cellular Cytokine Solution) in 3 Different Regimens With Standardized Care 0.9% Nacl in the Topical Treatment of Partial-thickness Burns | ||||
Brief Summary | The objective of this protocol is to perform a safety and dose-determination efficacy clinical trial in patients having a degree of partial-thickness burn wounds. The trial will be a prospectively randomized and double-blind trial of Amnion-derived Cellular Cytokine Solution (ACCS) compared with standardized care using 0.9% NaCl (normal saline) solution in the same three treatment regimens. |
||||
Detailed Description | A Phase I/II multi-center clinical trial will be performed in 99 adults with partial-thickness burns. Two similar partial-thickness burn areas in a single patient will be selected. One burn will be randomly assigned to receive either test drug (ACCS) or normal saline in one of three treatment regimens. The three treatment arms will be:
Two different preclinical studies of partial-thickness burns on guinea pigs have demonstrated accelerated epithelialization with topical treatment with ACCS. Similarly, preclinical studies in Yorkshire pigs have demonstrated more rapid maturity of epithelialization and better quality healing of partial-thickness skin graft donor sites with ACCS treatment. In the preclinical studies, ACCS given in a dose of 0.01 mL/cm2 wound area appeared to saturate the wound adequately without excess and simultaneously improve healing. In preclinical toxicity studies, the dose of 0.01 mL/cm2 was shown to be safe. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 1 Phase 2 |
||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||
Condition ICMJE | Burns | ||||
Intervention ICMJE | Biological: ACCS (Amnion-derived Cytokine Suspension)
ACCS is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds. |
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Estimated Enrollment ICMJE | 99 | ||||
Estimated Completion Date | March 2010 | ||||
Estimated Primary Completion Date | October 2009 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 65 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00886470 | ||||
Other Study ID Numbers ICMJE | ACCS-PT-09.001 | ||||
Has Data Monitoring Committee | Yes | ||||
Responsible Party | David L. Steed, MD Medical Monitor, Stemnion, Inc | ||||
Study Sponsor ICMJE | Stemnion, Inc. | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Stemnion, Inc. | ||||
Verification Date | March 2010 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |